Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 37
- Registration Number
- NCT01593228
- Locations
- 🇺🇸
Investigational Site Number 840025, Sioux City, Iowa, United States
🇺🇸Investigational Site Number 840030, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840043, Cleveland, Ohio, United States
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
- First Posted Date
- 2012-04-27
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT01587040
- Locations
- 🇺🇸
Investigational Site Number 840104, Fort Myers, Florida, United States
🇺🇸Investigational Site Number 840008, Los Angeles, California, United States
🇺🇸Investigational Site Number 840006, Augusta, Georgia, United States
A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 237
- Registration Number
- NCT01586338
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shangai, China
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT01576029
- Locations
- 🇧🇷
Investigational Site Number 004, Barretos, Brazil
🇧🇷Investigational Site Number 001, Rio De Janeiro, Brazil
🇧🇷Investigational Site Number 006, Rio De Janeiro, Brazil
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT01572649
- Locations
- 🇺🇸
Investigational Site Number 840001, Overland Park, Kansas, United States
🇺🇸Investigational Site Number 840003, Louisville, Kentucky, United States
🇬🇧Investigational Site Number 826001, Leeds, United Kingdom
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: FOLFIRI
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 781
- Registration Number
- NCT01571284
- Locations
- 🇧🇪
Investigational Site Number 056004, Bonheiden, Belgium
🇺🇸Investigational Site Number 840-009, Farmington, New Mexico, United States
🇩🇪Investigational Site Number 276-005, Weiden/Oberpfalz, Germany
Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
- Conditions
- Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)
- Interventions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT01567904
- Locations
- 🇭🇺
Investigational Site Number 348001, Budapest, Hungary
Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT01561781
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT01551615
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
- Conditions
- Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 103
- Registration Number
- NCT01551069
- Locations
- 🇯🇵
Investigational Site Number 392020, Maebashi-Shi, Japan
🇯🇵Investigational Site Number 392012, Nagasaki-Shi, Japan
🇯🇵Investigational Site Number 392013, Nakagami-Gun, Japan